Eli Lilly's Zepbound is now the first FDA-approved drug treatment for obstructive sleep apnea, adding a significant advancement in managing a prevalent chronic condition.
Mesoblast's remestemcel, branded as Ryoncil, is the first cell therapy approved for acute graft versus host disease and marks a breakthrough in regenerative medicine.
Vtama, approved by the FDA for atopic dermatitis, signifies a notable success in immunology treatments and reflects the ongoing innovation in dermatological therapies.
Collection
[
|
...
]